We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarkers Associated with Major Bleeding in Patients with Atrial Fibrillation

By LabMedica International staff writers
Posted on 16 Nov 2021
Print article
Image: The BioMark HD real-time Polymerase Chain reaction (PCR) platform (Photo courtesy of Fluidigm)
Image: The BioMark HD real-time Polymerase Chain reaction (PCR) platform (Photo courtesy of Fluidigm)
Atrial fibrillation (AF) is associated with a five-fold increased risk of thromboembolisms, mainly stroke, independently of other risk factors. Accurate assessment to balance the risk of stroke and systemic embolic events (S/SEE), against the risk of major bleeding is therefore an important therapeutic goal in the clinical management of these patients.

Age, prior hemorrhage, severe renal disease, and anemia (hemoglobin) have been independently associated with an increased risk of major bleeding in patients with AF. The use of different combinations of these mainly clinical variables has resulted in at least five validated risk scores for better prediction of bleeding events in patients with AF.

Medical Scientists at Uppsala University (Uppsala, Sweden) explored associations between a wide range of biomarkers and bleeding risk in patients with AF on oral anticoagulants (OAC). Biomarkers were analyzed in a random sample of 4,200 patients, 204 cases with major bleedings. The replication cohort included 344 cases with major bleeding and 1,024 random controls.

The plasma concentrations of high-sensitivity cTnT-hs, NT-proBNP, and GDF-15 were determined by Roche immunoassays using a Cobas Analytics e601 (Roche Diagnostics, Rotkreuz, Switzerland). Interleukin 6 (IL-6) was analyzed using the high-sensitivity sandwich ELISA immunoassay (R&D Systems Inc, Minneapolis, MN, USA) and Cystatin C with the ARCHITECT system ci8200 (Abbott Laboratories, Abbott Park, IL, USA) using the particle-enhanced turbidimetric immunoassay (PETIA) from Gentian Diagnostics ASA (Moss, Norway).

The proteomic analyses were performed with the high-throughput Proximity Extension Assay (PEA) technique using the Target 96 Multiplex CVD II, CVD III, and Inflammation panels (Olink Proteomics, Uppsala, Sweden), which together simultaneously measured 276 selected proteins in plasma potentially related to CVD and inflammation. The PEA technology uses pairs of antibodies equipped with DNA reporter molecules When binding to their correct targets, antibody pairs give rise to new DNA amplicons each ID-barcoding their respective antigens. The amplicons are subsequently quantified using the Fluidigm BioMark HD real-time PCR platform (Fluidigm, South San Francisco, CA, USA).

The investigators reported that out of 268 proteins, nine biomarkers were independently associated with bleeding in both cohorts. In the replication cohort a significant linear hazard ratios per interquartile range were confirmed for these biomarkers: cytokine GDF-15, cTnT-hs, osteopontin (OPN), ephrin type-B receptor 4 (EphB4), TNF-R1, TNF-R2, soluble urokinase plasminogen activator receptor (suPAR), TRAIL-R2, and osteoprotegerin (OPG).

The authors concluded that in patients with AF on OAC, GDF-15, cTnT-hs, and seven novel biomarkers were independently associated with major bleedings and reflect pathophysiologic processes of inflammation, apoptosis, oxidative stress, vascular calcification, coagulation, and fibrinolysis. Investigations of the utility of these markers to refine risk stratification and guide the management of patients at high risk of bleeding are warranted. The study was published on the November 2021 issue of the Journal of Thrombosis and Haemostasis.

Related Links:
Uppsala University
Roche Diagnostics
R&D Systems
Abbott Laboratories
Gentian Diagnostics
Olink Proteomics

Gold Supplier
Hemostasis Analyzer
STA R Max 3
ELISA Mini Workstation
Crocodile 5-in-one
Silver Supplier
Automated RPR Syphilis Test
Automated RPR Test Kit
Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT

Print article



view channel
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)

Siemens Introduces New Intelligent, Integrated IVD Solutions Virtually at EUROMEDLAB 2021

Siemens Healthineers (Erlangen, Germany) introduced new intelligent, integrated IVD solutions virtually at the XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab... Read more


view channel
Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)

Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers

Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing

The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.